Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a week of acid drugs double as a GERD test?

NCT ID NCT07826455

Diagnosis Sponsor: HK inno.N Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether early symptom relief from tegoprazan can help diagnose gastroesophageal reflux disease (GERD). Adults with frequent heartburn or acid regurgitation take tegoprazan or a placebo once daily for one week. By comparing symptom improvement between the groups, the study aims to see if a short drug response can serve as a diagnostic signal for GERD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tegoprazan, a potassium-competitive acid blocker
What this could lead to
If the approach works, doctors could use a one-week trial of tegoprazan to diagnose GERD without invasive tests like endoscopy.
What could go wrong
Symptom relief from a drug is an indirect signal, so it may not reliably separate GERD from other conditions. The trial is small and exploratory, and results may not hold in broader patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 19 to 75 years who have experienced symptoms of acid regurgitation or heartburn at least twice a week starting at least 3 months prior to screening. * Baseline Symptom Assessment Questionnaire score of at least 6 at screening. * 7-Day Symptom Assessment Questionnaire score of at least 4 at randomization. Exclusion Criteria: * Known hypersensitivity to Potassium-Competitive Acid Blockers (P-CABs) or benzimidazoles. * Presence of gastrointestinal warning symptoms (e.g., progressive dysphagia, bleeding, unintentional weight loss within 3 months, hematemesis, anemia, hematochezia, or rectal bleeding) without a confirmed negative tumor finding on endoscopy. * History of or planned gastrointestinal surgery that potentially affects gastric acid secretion. * Diagnosed with Zollinger-Ellison syndrome or other gastric acid secretion disorders. * Endoscopic evidence of esophageal stricture, ulcer stenosis, esophageal varices, Barrett's esophagus (\> 3 cm), eosinophilic esophagitis, gastrointestinal bleeding, active peptic ulcer, or malignant tumor. * Clinically significant hepatic or renal impairment (AST, ALT, ALP, GGT, total bilirubin, and creatinine greater than or equal to 2 times the upper limit of normal \[ULN\]) at Screening. * Use of any prohibited medications within the specified wash-out periods or requiring continuous use during the study: 1. Within 2 weeks prior to screening: Acid suppressants (PPIs, P-CABs). 2. Within 1 week prior to screening: Prokinetics, H2 receptor antagonists, gastric mucosal protectors, antacids, or anticholinergics. 3. During the study period (continuous use): Corticosteroids, NSAIDs, antithrombotics, anticoagulants, antipsychotics, antidepressants, or anxiolytics.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD (gastroesophageal reflux disease) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERD (gastroesophageal reflux disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.